+357 96 030922
info@marketpublishers.com

Global Risankizumab Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/GCC00851E49CEN.html
Date: September 2026
Pages: 87
Price: US$ 4,480.00 (Single User License)
ID: GCC00851E49CEN

Abstracts

The global Risankizumab market size is expected to reach $ 91604 million by 2032, rising at a market growth of 15.0% CAGR during the forecast period (2026-2032).

Risankizumab is a humanized monoclonal antibody that selectively binds the p19 subunit of interleukin-23, thereby inhibiting IL-23-mediated inflammatory signaling in chronic immune-mediated diseases. The research scope focuses on finished risankizumab medicines supplied through prefilled syringes, prefilled pens, on-body injectors with prefilled cartridges, and single-dose vials. The product is administered subcutaneously or intravenously, with treatment protocols structured around induction therapy and maintenance therapy according to the approved indication. Core applications cover plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, generalized pustular psoriasis, and erythrodermic psoriasis, subject to regional regulatory authorization. This study evaluates demand by dosage form, route of administration, treatment phase, therapeutic application, and geographic market, together with manufacturing, distribution, market access, and competitive positioning across the Risankizumab value chain.

Key Findings

In 2025, global Risankizumab production reached approximately 2685 k units

United States generated approximately 86% of 2024 product revenue

Selective IL-23 p19 inhibition defines the product's therapeutic mechanism

+357 96 030922
info@marketpublishers.com

Subcutaneous maintenance and intravenous induction support indication-specific treatment pathways

Dermatology and inflammatory bowel disease form the core application structure

AbbVie leads global development commercialization and branded market access

Japan maintains broader psoriasis subtype coverage than Western markets

Market Trends

The Risankizumab market is evolving from a predominantly dermatology-oriented product model into a multi-specialty immunology platform spanning dermatology, rheumatology, and gastroenterology. Product development is increasingly aligned with the clinical pathway of each disease: plaque psoriasis and psoriatic arthritis rely principally on infrequent subcutaneous administration, while Crohn’s disease and ulcerative colitis combine intravenous induction with subcutaneous maintenance. At the same time, prefilled pens, prefilled syringes, and on-body delivery systems are strengthening the role of self-administration and reducing the treatment burden associated with long-term biologic therapy. Future market development will increasingly depend on deeper penetration of approved indications, improved treatment persistence, broader reimbursement, device convenience, and the generation of comparative and real-world clinical evidence rather than reliance on a single initial indication.

Market Dynamics

Drivers

Demand for Risankizumab is supported by the chronic and recurrent nature of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, which creates sustained requirements for long-term disease control. Its selective IL-23 p19 mechanism, indication-specific induction and maintenance regimens, and relatively extended dosing intervals in psoriatic diseases support physician acceptance and patient adherence. Commercial growth is also being reinforced by the expansion from dermatology into inflammatory bowel disease, enabling the product to reach multiple specialist departments while leveraging a common immunology development, medical

+357 96 030922
info@marketpublishers.com

affairs, and market-access infrastructure.

Restraints

Market penetration remains constrained by the high acquisition cost of branded biologic therapy, reimbursement restrictions, treatment sequencing requirements, and differences in hospital access across countries. Manufacturing and distribution require controlled biological production, aseptic filling, device integration, quality release, and temperature-managed logistics, increasing operating complexity relative to conventional small-molecule medicines. Clinical use also requires screening and monitoring for infections and tuberculosis, while inflammatory bowel disease treatment involves additional liver-function monitoring during induction. These requirements can slow initiation, increase administrative burdens, and limit uptake in healthcare systems with restricted specialist resources or tightly managed pharmaceutical budgets.

Opportunities

The principal opportunity lies in increasing penetration within the existing application portfolio rather than changing the established product boundary. In inflammatory bowel disease, the transition from hospital-based intravenous induction to device-supported subcutaneous maintenance creates opportunities to combine specialist initiation with home-based long-term treatment. In dermatology and rheumatology, convenient prefilled delivery formats and extended maintenance intervals can support treatment persistence and conversion from less targeted therapies. China represents an additional access opportunity following regulatory expansion of risankizumab formulations and continued development of reimbursement pathways, although commercial realization will depend on hospital listing, physician education, patient affordability, and coordinated supply of induction and maintenance formulations.

Challenges

The long-term challenge is not limited to competition within the IL-23 inhibitor class. Risankizumab competes for treatment position against biologics and targeted therapies with different mechanisms, administration routes, safety profiles, reimbursement conditions, and levels of physician familiarity. Payers increasingly require evidence of comparative clinical value, durable response, treatment persistence, and total healthcare-resource benefits before granting broad access. The product must also

+357 96 030922
info@marketpublishers.com

maintain reliable global biological manufacturing and device supply while adapting to differing regulatory labels and treatment pathways. Any divergence between approved indications, reimbursement scope, hospital formularies, and actual clinical practice may delay commercialization even after regulatory approval.

Industry Chain Analysis

The upstream portion of the Risankizumab industry chain covers proprietary cell-line and process development, cell-culture media, biological raw materials, chromatography and filtration consumables, formulation excipients, primary packaging, and components for prefilled syringes, pens, cartridges, and on-body injectors. Midstream activities comprise mammalian-cell culture, protein purification, viral clearance, formulation, sterile filling, device assembly, analytical testing, batch release, and regulatory quality management. These operations require high capital investment, process consistency, validated facilities, and close coordination between drug-substance production, fill-finish operations, and delivery-device manufacturing.

Downstream commercialization connects specialty distributors, hospitals, infusion centers, dermatology and gastroenterology clinics, pharmacies, payers, and patient-support systems. Value creation is concentrated in intellectual property, clinical evidence, regulatory approvals, indication coverage, manufacturing reliability, dosing convenience, and reimbursement access. For inflammatory bowel disease, intravenous induction and subcutaneous maintenance create a more complex distribution pathway than psoriasis treatment, requiring continuity between institutional infusion and outpatient maintenance. Consequently, commercial performance depends not only on production capacity but also on cold-chain availability, specialist coverage, insurance negotiation, hospital formulary inclusion, and patient onboarding capabilities.

Segment Insights

By product form, prefilled pens and prefilled syringes constitute the principal configurations for subcutaneous administration in plaque psoriasis and psoriatic arthritis, reflecting their suitability for periodic outpatient or self-administered treatment. Prefilled cartridges used with on-body injectors are particularly relevant to higher-volume maintenance dosing in Crohn’s disease and ulcerative colitis. Single-dose vials support intravenous induction, making them an essential part of the inflammatory bowel disease treatment pathway even though their usage environment is more institutionally

+357 96 030922
info@marketpublishers.com

concentrated. The market therefore cannot be assessed solely by unit volume, because dosage strength, treatment phase, delivery device, and administration setting materially influence product value.

By treatment structure, maintenance therapy generates recurring long-term demand, while induction therapy functions as the entry point for eligible inflammatory bowel disease patients. Plaque psoriasis remains the foundational dermatology application, with psoriatic arthritis extending demand into rheumatology. Crohn's disease and ulcerative colitis broaden the commercial base toward gastroenterology and increase the importance of coordinated intravenous and subcutaneous supply. Generalized pustular psoriasis and erythrodermic psoriasis represent narrower, region-specific applications, particularly in Japan, and contribute to differentiation of the approved application portfolio rather than forming a uniform global segment.

Downstream Market Opportunities

Downstream opportunities are concentrated in specialist dermatology, rheumatology, and gastroenterology care. In dermatology, the main commercial requirement is sustained control of moderate-to-severe disease with manageable dosing frequency and convenient self-administration. Rheumatology demand depends on integration into psoriatic arthritis treatment sequencing and coordination with other disease-modifying therapies. Gastroenterology provides a structurally different opportunity because patients may begin treatment through hospital-based intravenous induction and subsequently shift to subcutaneous maintenance outside the infusion setting. This pathway creates demand for coordinated physician referral, patient training, pharmacy fulfillment, reimbursement authorization, and adherence support, making service quality and market access important determinants of downstream conversion.

Regional Insights

The United States is the dominant commercial market for Risankizumab, accounting for approximately 86% of the product's reported 2024 revenue. Its position reflects established specialist infrastructure, broad commercialization across dermatology, rheumatology, and gastroenterology, and substantial use of branded biologic therapies. Europe represents a diversified regional market governed by centralized regulatory authorization but country-specific pricing, reimbursement, and health-technology assessment processes. These differences can produce uneven launch timing and

+357 96 030922
info@marketpublishers.com

penetration despite common regional approval.

Japan is differentiated by broader psoriasis subtype coverage, including generalized pustular psoriasis and erythrodermic psoriasis, alongside the principal global indications. China is progressing through formulation approvals and reimbursement development, creating potential for increased access but also requiring alignment among regulatory status, national reimbursement, hospital procurement, and clinical adoption. Other emerging markets remain sensitive to biologic affordability, specialist availability, diagnostic capacity, and cold-chain infrastructure, resulting in a more gradual commercialization pattern than in established markets.

Competitive Landscape Analysis

The Risankizumab market has a highly concentrated branded structure, with AbbVie controlling the principal product development, regulatory, manufacturing, and commercialization platform. Competition therefore occurs primarily at the therapeutic-class and treatment-pathway levels rather than among multiple manufacturers of the same active ingredient. The product's competitive positioning is supported by selective IL-23 p19 inhibition, coverage across both psoriatic diseases and inflammatory bowel disease, extended subcutaneous maintenance intervals, and a portfolio of delivery formats adapted to different clinical settings. However, sustainable positioning requires continued investment in comparative evidence, real-world outcomes, physician engagement, reimbursement negotiation, patient-support programs, and reliable biological manufacturing. As alternative biologics and targeted oral therapies compete for earlier treatment placement, commercial advantage will increasingly depend on access, treatment persistence, device usability, and cross-specialty execution rather than mechanism differentiation alone.

Report Scope

This report studies the global Risankizumab production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Risankizumab and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Risankizumab that contribute to its

+357 96 030922
info@marketpublishers.com

increasing demand across many markets.

Highlights and key features of the study

Global Risankizumab total production and demand, 2021-2032, (K Units)

Global Risankizumab total production value, 2021-2032, (USD Million)

Global Risankizumab production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)

Global Risankizumab consumption by region & country, CAGR, 2021-2032 & (K Units)

U.S. VS China: Risankizumab domestic production, consumption, key domestic manufacturers and share

Global Risankizumab production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)

Global Risankizumab production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)

Global Risankizumab production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)

This report profiles key players in the global Risankizumab market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Risankizumab market

+357 96 030922
info@marketpublishers.com

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Risankizumab Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Market Segmentation

Global Risankizumab Market, Segmentation by Type:

Prefilled Syringe

Prefilled Pen

Single-Dose Vial

+357 96 030922
info@marketpublishers.com

Global Risankizumab Market, Segmentation by Administration:

Subcutaneous Administration

Intravenous Administration

Global Risankizumab Market, Segmentation by Therapy:

Induction Therapy

Maintenance Therapy

Global Risankizumab Market, Segmentation by Application:

Plaque Psoriasis

Psoriatic Arthritis

Crohn's Disease

Ulcerative Colitis

Other

Companies Profiled:

AbbVie

Key Questions Answered

1. How big is the global Risankizumab market?
2. What is the demand of the global Risankizumab market?

+357 96 030922
info@marketpublishers.com

3. What is the year over year growth of the global Risankizumab market?
4. What is the total value of the global Risankizumab market?
5. Who are the Major Players in the global Risankizumab market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

1 SUPPLY SUMMARY

1.1 Risankizumab Introduction
1.2 World Risankizumab Supply & Forecast
  1.2.1 World Risankizumab Production Value (2021 & 2025 & 2032)
  1.2.2 World Risankizumab Production (2021-2032)
  1.2.3 World Risankizumab Pricing Trends (2021-2032)
1.3 World Risankizumab Production by Region (Based on Production Site)
  1.3.1 World Risankizumab Production Value by Region (2021-2032)
  1.3.2 World Risankizumab Production by Region (2021-2032)
  1.3.3 World Risankizumab Average Price by Region (2021-2032)
  1.3.4 North America Risankizumab Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Risankizumab Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Risankizumab Major Market Trends

2 DEMAND SUMMARY

2.1 World Risankizumab Demand (2021-2032)
2.2 World Risankizumab Consumption by Region
  2.2.1 World Risankizumab Consumption by Region (2021-2026)
  2.2.2 World Risankizumab Consumption Forecast by Region (2027-2032)
2.3 United States Risankizumab Consumption (2021-2032)
2.4 China Risankizumab Consumption (2021-2032)
2.5 Europe Risankizumab Consumption (2021-2032)
2.6 Japan Risankizumab Consumption (2021-2032)
2.7 South Korea Risankizumab Consumption (2021-2032)
2.8 ASEAN Risankizumab Consumption (2021-2032)
2.9 India Risankizumab Consumption (2021-2032)

3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS

3.1 World Risankizumab Production Value by Manufacturer (2021-2026)
3.2 World Risankizumab Production by Manufacturer (2021-2026)
3.3 World Risankizumab Average Price by Manufacturer (2021-2026)
3.4 Risankizumab Company Evaluation Quadrant

+357 96 030922
info@marketpublishers.com

3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Risankizumab Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Risankizumab in 2025
3.5.3 Global Concentration Ratios (CR8) for Risankizumab in 2025
3.6 Risankizumab Market: Overall Company Footprint Analysis
3.6.1 Risankizumab Market: Region Footprint
3.6.2 Risankizumab Market: Company Product Type Footprint
3.6.3 Risankizumab Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations

4 UNITED STATES VS CHINA VS REST OF THE WORLD

4.1 United States VS China: Risankizumab Production Value Comparison
4.1.1 United States VS China: Risankizumab Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Risankizumab Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Risankizumab Production Comparison
4.2.1 United States VS China: Risankizumab Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Risankizumab Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Risankizumab Consumption Comparison
4.3.1 United States VS China: Risankizumab Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Risankizumab Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Risankizumab Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Risankizumab Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Risankizumab Production Value (2021-2026)
4.4.3 United States Based Manufacturers Risankizumab Production (2021-2026)
4.5 China Based Risankizumab Manufacturers and Market Share

+357 96 030922
info@marketpublishers.com

4.5.1 China Based Risankizumab Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Risankizumab Production Value (2021-2026)
4.5.3 China Based Manufacturers Risankizumab Production (2021-2026)
4.6 Rest of World Based Risankizumab Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Risankizumab Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Risankizumab Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Risankizumab Production (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Risankizumab Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Prefilled Syringe
5.2.2 Prefilled Pen
5.2.3 Single-Dose Vial
5.3 Market Segment by Type
5.3.1 World Risankizumab Production by Type (2021-2032)
5.3.2 World Risankizumab Production Value by Type (2021-2032)
5.3.3 World Risankizumab Average Price by Type (2021-2032)

6 MARKET ANALYSIS BY ADMINISTRATION

6.1 World Risankizumab Market Size Overview by Administration: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Administration
6.2.1 Subcutaneous Administration
6.2.2 Intravenous Administration
6.3 Market Segment by Administration
6.3.1 World Risankizumab Production by Administration (2021-2032)
6.3.2 World Risankizumab Production Value by Administration (2021-2032)
6.3.3 World Risankizumab Average Price by Administration (2021-2032)

7 MARKET ANALYSIS BY THERAPY

7.1 World Risankizumab Market Size Overview by Therapy: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Therapy

+357 96 030922
info@marketpublishers.com

7.2.1 Induction Therapy
7.2.2 Maintenance Therapy
7.3 Market Segment by Therapy
7.3.1 World Risankizumab Production by Therapy (2021-2032)
7.3.2 World Risankizumab Production Value by Therapy (2021-2032)
7.3.3 World Risankizumab Average Price by Therapy (2021-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World Risankizumab Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Plaque Psoriasis
8.2.2 Psoriatic Arthritis
8.2.3 Crohn's Disease
8.2.4 Ulcerative Colitis
8.2.5 Other
8.3 Market Segment by Application
8.3.1 World Risankizumab Production by Application (2021-2032)
8.3.2 World Risankizumab Production Value by Application (2021-2032)
8.3.3 World Risankizumab Average Price by Application (2021-2032)

9 COMPANY PROFILES

9.1 AbbVie
9.1.1 AbbVie Details
9.1.2 AbbVie Major Business
9.1.3 AbbVie Risankizumab Product and Services
9.1.4 AbbVie Risankizumab Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 AbbVie Recent Developments/Updates
9.1.6 AbbVie Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 Risankizumab Industry Chain
10.2 Risankizumab Upstream Analysis
10.2.1 Risankizumab Core Raw Materials
10.2.2 Main Manufacturers of Risankizumab Core Raw Materials
10.3 Midstream Analysis

+357 96 030922
info@marketpublishers.com

10.4 Downstream Analysis
10.5 Risankizumab Production Mode
10.6 Risankizumab Procurement Model
10.7 Risankizumab Industry Sales Model and Sales Channels
10.7.1 Risankizumab Sales Model
10.7.2 Risankizumab Typical Distributors

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. World Risankizumab Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Risankizumab Production Value by Region (2021-2026) & (USD Million)
Table 3. World Risankizumab Production Value by Region (2027-2032) & (USD Million)
Table 4. World Risankizumab Production Value Market Share by Region (2021-2026)
Table 5. World Risankizumab Production Value Market Share by Region (2027-2032)
Table 6. World Risankizumab Production by Region (2021-2026) & (K Units)
Table 7. World Risankizumab Production by Region (2027-2032) & (K Units)
Table 8. World Risankizumab Production Market Share by Region (2021-2026)
Table 9. World Risankizumab Production Market Share by Region (2027-2032)
Table 10. World Risankizumab Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Risankizumab Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Risankizumab Major Market Trends
Table 13. World Risankizumab Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Risankizumab Consumption by Region (2021-2026) & (K Units)
Table 15. World Risankizumab Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Risankizumab Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Risankizumab Producers in 2025
Table 18. World Risankizumab Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Risankizumab Producers in 2025
Table 20. World Risankizumab Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Risankizumab Company Evaluation Quadrant
Table 22. World Risankizumab Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Risankizumab Production Site of Key Manufacturer
Table 24. Risankizumab Market: Company Product Type Footprint
Table 25. Risankizumab Market: Company Product Application Footprint
Table 26. Risankizumab Competitive Factors
Table 27. Risankizumab New Entrant and Capacity Expansion Plans
Table 28. Risankizumab Mergers & Acquisitions Activity
Table 29. United States VS China Risankizumab Production Value Comparison, (2021

+357 96 030922
info@marketpublishers.com

& 2025 & 2032) & (USD Million)
Table 30. United States VS China Risankizumab Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Risankizumab Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Risankizumab Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Risankizumab Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Risankizumab Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Risankizumab Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Risankizumab Production Market Share (2021-2026)
Table 37. China Based Risankizumab Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Risankizumab Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Risankizumab Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Risankizumab Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Risankizumab Production Market Share (2021-2026)
Table 42. Rest of World Based Risankizumab Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Risankizumab Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Risankizumab Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Risankizumab Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Risankizumab Production Market Share (2021-2026)
Table 47. World Risankizumab Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Risankizumab Production by Type (2021-2026) & (K Units)
Table 49. World Risankizumab Production by Type (2027-2032) & (K Units)

+357 96 030922
info@marketpublishers.com

Table 50. World Risankizumab Production Value by Type (2021-2026) & (USD Million)
Table 51. World Risankizumab Production Value by Type (2027-2032) & (USD Million)
Table 52. World Risankizumab Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Risankizumab Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Risankizumab Production Value by Administration, (USD Million), 2021 & 2025 & 2032
Table 55. World Risankizumab Production by Administration (2021-2026) & (K Units)
Table 56. World Risankizumab Production by Administration (2027-2032) & (K Units)
Table 57. World Risankizumab Production Value by Administration (2021-2026) & (USD Million)
Table 58. World Risankizumab Production Value by Administration (2027-2032) & (USD Million)
Table 59. World Risankizumab Average Price by Administration (2021-2026) & (US$/Unit)
Table 60. World Risankizumab Average Price by Administration (2027-2032) & (US$/Unit)
Table 61. World Risankizumab Production Value by Therapy, (USD Million), 2021 & 2025 & 2032
Table 62. World Risankizumab Production by Therapy (2021-2026) & (K Units)
Table 63. World Risankizumab Production by Therapy (2027-2032) & (K Units)
Table 64. World Risankizumab Production Value by Therapy (2021-2026) & (USD Million)
Table 65. World Risankizumab Production Value by Therapy (2027-2032) & (USD Million)
Table 66. World Risankizumab Average Price by Therapy (2021-2026) & (US$/Unit)
Table 67. World Risankizumab Average Price by Therapy (2027-2032) & (US$/Unit)
Table 68. World Risankizumab Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Risankizumab Production by Application (2021-2026) & (K Units)
Table 70. World Risankizumab Production by Application (2027-2032) & (K Units)
Table 71. World Risankizumab Production Value by Application (2021-2026) & (USD Million)
Table 72. World Risankizumab Production Value by Application (2027-2032) & (USD Million)
Table 73. World Risankizumab Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World Risankizumab Average Price by Application (2027-2032) & (US$/Unit)
Table 75. AbbVie Basic Information, Manufacturing Base and Competitors
Table 76. AbbVie Major Business
Table 77. AbbVie Risankizumab Product and Services

+357 96 030922
info@marketpublishers.com

Table 78. AbbVie Risankizumab Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. AbbVie Recent Developments/Updates
Table 80. AbbVie Competitive Strengths & Weaknesses
Table 81. Global Key Players of Risankizumab Upstream (Raw Materials)
Table 82. Global Risankizumab Typical Customers
Table 83. Risankizumab Typical Distributors

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Risankizumab Picture
Figure 2. World Risankizumab Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Risankizumab Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Risankizumab Production (2021-2032) & (K Units)
Figure 5. World Risankizumab Average Price (2021-2032) & (US$/Unit)
Figure 6. World Risankizumab Production Value Market Share by Region (2021-2032)
Figure 7. World Risankizumab Production Market Share by Region (2021-2032)
Figure 8. North America Risankizumab Production (2021-2032) & (K Units)
Figure 9. Risankizumab Market Drivers
Figure 10. Factors Affecting Demand
Figure 11. World Risankizumab Consumption (2021-2032) & (K Units)
Figure 12. World Risankizumab Consumption Market Share by Region (2021-2032)
Figure 13. United States Risankizumab Consumption (2021-2032) & (K Units)
Figure 14. China Risankizumab Consumption (2021-2032) & (K Units)
Figure 15. Europe Risankizumab Consumption (2021-2032) & (K Units)
Figure 16. Japan Risankizumab Consumption (2021-2032) & (K Units)
Figure 17. South Korea Risankizumab Consumption (2021-2032) & (K Units)
Figure 18. ASEAN Risankizumab Consumption (2021-2032) & (K Units)
Figure 19. India Risankizumab Consumption (2021-2032) & (K Units)
Figure 20. Producer Shipments of Risankizumab by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 21. Global Four-firm Concentration Ratios (CR4) for Risankizumab Markets in 2025
Figure 22. Global Four-firm Concentration Ratios (CR8) for Risankizumab Markets in 2025
Figure 23. United States VS China: Risankizumab Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 24. United States VS China: Risankizumab Production Market Share Comparison (2021 & 2025 & 2032)
Figure 25. United States VS China: Risankizumab Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 26. United States Based Manufacturers Risankizumab Production Market Share 2025
Figure 27. China Based Manufacturers Risankizumab Production Market Share 2025

+357 96 030922
info@marketpublishers.com

Figure 28. Rest of World Based Manufacturers Risankizumab Production Market Share 2025
Figure 29. World Risankizumab Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Risankizumab Production Value Market Share by Type in 2025
Figure 31. Prefilled Syringe
Figure 32. Prefilled Pen
Figure 33. Single-Dose Vial
Figure 34. World Risankizumab Production Market Share by Type (2021-2032)
Figure 35. World Risankizumab Production Value Market Share by Type (2021-2032)
Figure 36. World Risankizumab Average Price by Type (2021-2032) & (US$/Unit)
Figure 37. World Risankizumab Production Value by Administration, (USD Million), 2021 & 2025 & 2032
Figure 38. World Risankizumab Production Value Market Share by Administration in 2025
Figure 39. Subcutaneous Administration
Figure 40. Intravenous Administration
Figure 41. World Risankizumab Production Market Share by Administration (2021-2032)
Figure 42. World Risankizumab Production Value Market Share by Administration (2021-2032)
Figure 43. World Risankizumab Average Price by Administration (2021-2032) & (US$/Unit)
Figure 44. World Risankizumab Production Value by Therapy, (USD Million), 2021 & 2025 & 2032
Figure 45. World Risankizumab Production Value Market Share by Therapy in 2025
Figure 46. Induction Therapy
Figure 47. Maintenance Therapy
Figure 48. World Risankizumab Production Market Share by Therapy (2021-2032)
Figure 49. World Risankizumab Production Value Market Share by Therapy (2021-2032)
Figure 50. World Risankizumab Average Price by Therapy (2021-2032) & (US$/Unit)
Figure 51. World Risankizumab Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 52. World Risankizumab Production Value Market Share by Application in 2025
Figure 53. Plaque Psoriasis
Figure 54. Psoriatic Arthritis
Figure 55. Crohn's Disease
Figure 56. Ulcerative Colitis
Figure 57. Other

+357 96 030922
info@marketpublishers.com

Figure 58. World Risankizumab Production Market Share by Application (2021-2032)
Figure 59. World Risankizumab Production Value Market Share by Application (2021-2032)
Figure 60. World Risankizumab Average Price by Application (2021-2032) & (US$/Unit)
Figure 61. Risankizumab Industry Chain
Figure 62. Risankizumab Procurement Model
Figure 63. Risankizumab Sales Model
Figure 64. Risankizumab Sales Channels, Direct Sales, and Distribution
Figure 65. Methodology
Figure 66. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Risankizumab Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/GCC00851E49CEN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GCC00851E49CEN.html